New views on antidepressant action

Current Opinion in Neurobiology

Volumn 21, Issue 6, 2011, Pages 858-865

  Baudry, Anne ^a   Mouillet Richard, Sophie ^a   Launay, Jean Marie ^b,c   Kellermann, Odile ^a  

^a INSERM   (France)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; AMPA RECEPTOR; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; FLUOXETINE; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; KETAMINE; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 16; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROTEIN S100B; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; WNT2 PROTEIN;

BRAIN DERIVED NEUROTROPHIC FACTOR GENE; CIRCADIAN RHYTHM; DENTATE GYRUS; DEPRESSION; EPIGENETICS; GENE; HIPPOCAMPUS; HUMAN; LOCUS CERULEUS; MAJOR DEPRESSION; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSION; HUMANS; NEURONAL PLASTICITY; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

EID: 80155146744     PISSN: 09594388     EISSN: 18736882     Source Type: Journal    
DOI: 10.1016/j.conb.2011.03.005     Document Type: Review

References (67)

1. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455:894-902.
2. Pittenger C., Duman R.S. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008, 33:88-109.
3. Ban T.A. Pharmacotherapy of depression: a historical analysis. J Neural Transm 2001, 108:707-716.
4. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965, 122:509-522.
5. Luscher B, Shen Q, Sahir N: The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry 2010, 16:383-406.
6. Mitchell N.D., Baker G.B. An update on the role of glutamate in the pathophysiology of depression. Acta Psychiatr Scand 2010, 122:192-210.
7. Mineur Y.S., Picciotto M.R. Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci 2010, 31:580-586.
8. Frazer A., Morilak D.A. What should animal models of depression model?. Neurosci Biobehav Rev 2005, 29:515-523.
9. Perona M.T., Waters S., Hall F.S., Sora I., Lesch K.P., Murphy D.L., Caron M., Uhl G.R. Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions. Behav Pharmacol 2008, 19:566-574.
10. Nestler E.J., Hyman S.E. Animal models of neuropsychiatric disorders. Nat Neurosci 2010, 13:1161-1169.
11. Duman R.S. Depression: a case of neuronal life and death?. Biol Psychiatry 2004, 56:140-145.
12. Macqueen G., Frodl T. The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research?. Mol Psychiatry 2010, 16:252-264.
13. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., Weisstaub N., Lee J., Duman R., Arancio O., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
14. Boldrini M., Underwood M.D., Hen R., Rosoklija G.B., Dwork A.J., John Mann J., Arango V. Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology 2009, 34:2376-2389.
15. Castren E., Rantamaki T. The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev Neurobiol 2010, 70:289-297.
16. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59:1116-1127.
17. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002, 22:3251-3261.
18. Adachi M., Barrot M., Autry A.E., Theobald D., Monteggia L.M. Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. Biol Psychiatry 2008, 63:642-649.
19. Li Y., Luikart B.W., Birnbaum S., Chen J., Kwon C.H., Kernie S.G., Bassel-Duby R., Parada L.F. TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron 2008, 59:399-412.
20. Sairanen M., Lucas G., Ernfors P., Castren M., Castren E. Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J Neurosci 2005, 25:1089-1094.
21. Taliaz D., Stall N., Dar D.E., Zangen A. Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis. Mol Psychiatry 2010, 15:80-92.
22. Warner-Schmidt J.L., Chen E.Y., Zhang X., Marshall J.J., Morozov A., Svenningsson P., Greengard P. A role for p11 in the antidepressant action of brain-derived neurotrophic factor. Biol Psychiatry 2010, 68:528-535.
23. Svenningsson P., Chergui K., Rachleff I., Flajolet M., Zhang X., El Yacoubi M., Vaugeois J.M., Nomikos G.G., Greengard P. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 2006, 311:77-80.
24. Egeland M., Warner-Schmidt J., Greengard P., Svenningsson P. Neurogenic effects of fluoxetine are attenuated in p11 (S100A10) knockout mice. Biol Psychiatry 2010, 67:1048-1056.
25. Ruf B.M., Bhagwagar Z. The 5-HT1B receptor: a novel target for the pathophysiology of depression. Curr Drug Targets 2009, 10:1118-1138.
26. Alexander B., Warner-Schmidt J., Eriksson T., Tamminga C., Arango-Llievano M., Ghose S., Vernov M., Stavarche M., Musatov S., Flajolet M., et al. Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci Transl Med 2010, 2. 54ra76.
27. Martinowich K., Manji H., Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci 2007, 10:1089-1093.
28. Schmidt HD, Duman RS: Peripheral BDNF Produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 2010, 35:2378-2391.
29. Tsai S.J. The P11, tPA/plasminogen system and brain-derived neurotrophic factor: implications for the pathogenesis of major depression and the therapeutic mechanism of antidepressants. Med Hypotheses 2007, 68:180-183.
30. Malberg J.E., Monteggia LM VGF, a new player in antidepressant action?. Sci Signal 2008, 1:pe19.
31. Wada A. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades. J Pharmacol Sci 2009, 110:14-28.
32. Gould T.D., Chen G., Manji H.K. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 2004, 29:32-38.
33. Beaulieu J.M., Caron M.G. Looking at lithium: molecular moods and complex behaviour. Mol Interv 2008, 8:230-241.
34. Polter A., Beurel E., Yang S., Garner R., Song L., Miller C.A., Sweatt J.D., McMahon L., Bartolucci A.A., Li X., et al. Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology 2010, 35:1761-1774.
35. Eom T.Y., Jope R.S. Blocked inhibitory serine-phosphorylation of glycogen synthase kinase-3alpha/beta impairs in vivo neural precursor cell proliferation. Biol Psychiatry 2009, 66:494-502.
36. Li X., Zhu W., Roh M.S., Friedman A.B., Rosborough K., Jope R.S. In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 2004, 29:1426-1431.
37. Omata N., Chiu C.T., Moya P.R., Leng Y., Wang Z., Hunsberger J.G., Leeds P., Chuang DM Lentivirally mediated GSK-3beta silencing in the hippocampal dentate gyrus induces antidepressant-like effects in stressed mice. Int J Neuropsychopharmacol 2010, 1-7.
38. Okamoto H., Voleti B., Banasr M., Sarhan M., Duric V., Girgenti M.J., Dileone R.J., Newton S.S., Duman R.S. Wnt2 expression and signaling is increased by different classes of antidepressant treatments. Biol Psychiatry 2010, 68:521-527.
39. Wayman G.A., Impey S., Marks D., Saneyoshi T., Grant W.F., Derkach V., Soderling T.R. Activity-dependent dendritic arborization mediated by CaM-kinase I activation and enhanced CREB-dependent transcription of Wnt-2. Neuron 2006, 50:897-909.
40. Blendy J.A. The role of CREB in depression and antidepressant treatment. Biol Psychiatry 2006, 59:1144-1150.
41. Jope R.S., Roh M.S. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 2006, 7:1421-1434.
42. Tsankova N.M., Berton O., Renthal W., Kumar A., Neve R.L., Nestler E.J. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006, 9:519-525.
43. Tsankova N., Renthal W., Kumar A., Nestler E.J. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007, 8:355-367.
44. Covington H.E., Maze I., LaPlant Q.C., Vialou V.F., Ohnishi Y.N., Berton O., Fass D.M., Renthal W., Rush A.J., Wu E.Y., et al. Antidepressant actions of histone deacetylase inhibitors. J Neurosci 2009, 29:11451-11460.
45. Schroeder F.A., Lin C.L., Crusio W.E., Akbarian S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol Psychiatry 2007, 62:55-64.
46. Wilkinson M.B., Xiao G., Kumar A., LaPlant Q., Renthal W., Sikder D., Kodadek T.J., Nestler E.J. Imipramine treatment and resiliency exhibit similar chromatin regulation in the mouse nucleus accumbens in depression models. J Neurosci 2009, 29:7820-7832.
47. Jiang Y., Jakovcevski M., Bharadwaj R., Connor C., Schroeder F.A., Lin C.L., Straubhaar J., Martin G., Akbarian S. Setdb1 histone methyltransferase regulates mood-related behaviors and expression of the NMDA receptor subunit NR2B. J Neurosci 2010, 30:7152-7167.
48. LaPlant Q., Vialou V., Covington H.E., Dumitriu D., Feng J., Warren B.L., Maze I., Dietz D.M., Watts E.L., Iniguez S.D., et al. Dnmt3a regulates emotional behavior and spine plasticity in the nucleus accumbens. Nat Neurosci 2010, 13:1137-1143.
49. Borrelli E., Nestler E.J., Allis C.D., Sassone-Corsi P. Decoding the epigenetic language of neuronal plasticity. Neuron 2008, 60:961-974.
50. Baudry A., Mouillet-Richard S., Schneider B., Launay J.M., Kellermann O. MiR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science 2010, 329:1537-1541.
51. Schratt G. microRNAs at the synapse. Nat Rev Neurosci 2009, 10:842-849.
52. Mendlewicz J. Disruption of the circadian timing systems: molecular mechanisms in mood disorders. CNS Drugs 2009, 23 Suppl. 2:15-26.
53. Monteleone P, Martiadis V, Maj M: Circadian rhythms and treatment implications in depression. Prog Neuropsychopharmacol Biol Psychiatry 2010, in press.
54. de Bodinat C., Guardiola-Lemaitre B., Mocaer E., Renard P., Munoz C., Millan M.J. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 2010, 9:628-642.
55. Dagyte G., Crescente I., Postema F., Seguin L., Gabriel C., Mocaer E., Boer J.A., Koolhaas J.M. Agomelatine reverses the decrease in hippocampal cell survival induced by chronic mild stress. Behav Brain Res 2010, 218:121-128.
56. Dagyte G., Trentani A., Postema F., Luiten P.G., Den Boer J.A., Gabriel C., Mocaer E., Meerlo P., Van der Zee E.A. The novel antidepressant agomelatine normalizes hippocampal neuronal activity and promotes neurogenesis in chronically stressed rats. CNS Neurosci Ther 2010, 16:195-207.
57. Soumier A., Banasr M., Lortet S., Masmejean F., Bernard N., Kerkerian-Le-Goff L., Gabriel C., Millan M.J., Mocaer E., Daszuta A. Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology 2009, 34:2390-2403.
58. Iitaka C., Miyazaki K., Akaike T., Ishida N. A role for glycogen synthase kinase-3beta in the mammalian circadian clock. J Biol Chem 2005, 280:29397-29402.
59. Hashimoto K: The role of glutamate on the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2010, in press.
60. Cryan J.F., O'Leary O.F. Neuroscience. A glutamate pathway to faster-acting antidepressants?. Science 2010, 329:913-914.
61. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., Li X.Y., Aghajanian G., Duman R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
62. Pei L., Li S., Wang M., Diwan M., Anisman H., Fletcher P.J., Nobrega J.N., Liu F. Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects. Nat Med 2010, 16:1393-1395.
63. Duric V., Banasr M., Licznerski P., Schmidt H.D., Stockmeier C.A., Simen A.A., Newton S.S., Duman R.S. A negative regulator of MAP kinase causes depressive behavior. Nat Med 2010, 16:1328-1332.
64. Tanti A., Belzung C. Open questions in current models of antidepressant action. Br J Pharmacol 2010, 159:1187-1200.
65. Dudley KJ, Li X, Kobor MS, Kippin TE, Bredy TW: Epigenetic mechanisms mediating vulnerability and resilience to psychiatric disorders. Neurosci Biobehav Rev 2011, in press.
66. Lesch KP: When the serotonin transporter gene meets adversity: the contribution of animal models to understanding epigenetic mechanisms in affective disorders and resilience. Curr Top Behav Neurosci 2011, 7:251-280.
67. Feder A., Nestler E.J., Charney D.S. Psychobiology and molecular genetics of resilience. Nat Rev Neurosci 2009, 10:446-457.